The Use of Olanzapine Versus Metoclopramide for the Treatment of Breakthrough Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

被引：0
|
作者：
Navari, Rudolph [1 ,2 ]
Nagy, Cindy [1 ]
Gray, Sarah [2 ]
机构：
[1] Indiana Univ Sch Med, South Bend, IN USA
[2] Univ Notre Dame, Notre Dame, IN 46556 USA
来源：
PSYCHO-ONCOLOGY | 2013年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [41] Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy
    Saldanha, S. C.
    Dasappa, L.
    Jacob, L. A.
    Babu, S. M.
    Lokesh, K. N.
    Rudresha, A. H.
    Lakkavalli, R. K.
    Kumar, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Olanzapine and palonosetron without dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: A proof-of-concept trial.
    Kim, Hee Jun
    Ha, Joo Young
    Oh, Edward Hyunseung
    Park, Song Ee
    Yi, Jun Ho
    Jang, Joung Soon
    Hwang, In Gyu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
    Eghbali, Aziz
    Bagherloo, Tahereh
    Ghasemi, Ali
    Afzal, Roghayeh
    Eghbali, Aygin
    Ghaffari, Kazem
    ADVANCED BIOMEDICAL RESEARCH, 2023, 12 (01): : 158
  • [44] Chemotherapy Induced Nausea and Vomiting and Quality of Life of Patients On Moderate And Highly Emetogenic Chemotherapy
    Mahidin, Eznal Izwadi Bin Mohd
    Ishak, Wan Zamaniah Binti Wan
    ANNALS OF ONCOLOGY, 2019, 30 : 128 - 128
  • [45] The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy
    Miura, Satoru
    Watanabe, Satoshi
    Sato, Kazuhiro
    Makino, Masato
    Kobayashi, Osamu
    Miyao, Hiromi
    Iwashima, Akira
    Okajima, Masaaki
    Tanaka, Junta
    Tanaka, Hiroshi
    Kagamu, Hiroshi
    Yokoyama, Akira
    Narita, Ichiei
    Yoshizawa, Hirohisa
    SUPPORTIVE CARE IN CANCER, 2013, 21 (09) : 2575 - 2581
  • [46] EFFICACY OF TRIPLET ANTIEMETIC THERAPY FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN LUNG CANCER PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY: PALONOSETRON, APREPITANT, AND DEXAMETHASONE
    Hayashi, M.
    Miura, S.
    Sato, K.
    Makino, M.
    Kobayashi, O.
    Miyao, H.
    Iwashima, A.
    Ichikawa, K.
    Koshio, J.
    Watanabe, S.
    Tanaka, J.
    Kagamu, H.
    Yokoyama, A.
    Narita, I.
    Yoshizawa, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 88 - 88
  • [47] Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC)
    Schwartzberg, Lee
    Szabo, Stephen
    Gilmore, James
    Haislip, Sally
    Jackson, James
    Jain, Gagan
    Balu, Sanjeev
    Buchner, Deborah
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (04) : 837 - 845
  • [48] The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy
    Satoru Miura
    Satoshi Watanabe
    Kazuhiro Sato
    Masato Makino
    Osamu Kobayashi
    Hiromi Miyao
    Akira Iwashima
    Masaaki Okajima
    Junta Tanaka
    Hiroshi Tanaka
    Hiroshi Kagamu
    Akira Yokoyama
    Ichiei Narita
    Hirohisa Yoshizawa
    Supportive Care in Cancer, 2013, 21 : 2575 - 2581
  • [49] Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong
    Chan, Stephen L.
    Jen, Jason
    Burke, Thomas
    Pellissier, James
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (01) : 80 - 91
  • [50] Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine
    Bosnjak, Snezana M.
    Dimitrijevic, Jelena
    Djordjevic, Fedja
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2016, 10 (02) : 180 - 188
12345